AU2021349262A1 - Piperazine-based cationic lipids - Google Patents

Piperazine-based cationic lipids Download PDF

Info

Publication number
AU2021349262A1
AU2021349262A1 AU2021349262A AU2021349262A AU2021349262A1 AU 2021349262 A1 AU2021349262 A1 AU 2021349262A1 AU 2021349262 A AU2021349262 A AU 2021349262A AU 2021349262 A AU2021349262 A AU 2021349262A AU 2021349262 A1 AU2021349262 A1 AU 2021349262A1
Authority
AU
Australia
Prior art keywords
compound
optionally substituted
pharmaceutically acceptable
acceptable salt
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021349262A
Other languages
English (en)
Other versions
AU2021349262A9 (en
Inventor
Ramesh Dasari
Saswata KARMAKAR
Ryan Landis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Translate Bio Inc
Original Assignee
Translate Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Translate Bio Inc filed Critical Translate Bio Inc
Publication of AU2021349262A1 publication Critical patent/AU2021349262A1/en
Publication of AU2021349262A9 publication Critical patent/AU2021349262A9/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Manufacturing & Machinery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AU2021349262A 2020-09-23 2021-09-23 Piperazine-based cationic lipids Pending AU2021349262A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063082101P 2020-09-23 2020-09-23
US63/082,101 2020-09-23
PCT/US2021/051763 WO2022066916A1 (en) 2020-09-23 2021-09-23 Piperazine-based cationic lipids

Publications (2)

Publication Number Publication Date
AU2021349262A1 true AU2021349262A1 (en) 2023-06-08
AU2021349262A9 AU2021349262A9 (en) 2025-03-13

Family

ID=78414070

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021349262A Pending AU2021349262A1 (en) 2020-09-23 2021-09-23 Piperazine-based cationic lipids

Country Status (12)

Country Link
US (1) US20230357166A1 (cg-RX-API-DMAC10.html)
EP (1) EP4216933B1 (cg-RX-API-DMAC10.html)
JP (1) JP7791182B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230074526A (cg-RX-API-DMAC10.html)
CN (1) CN116457027A (cg-RX-API-DMAC10.html)
AU (1) AU2021349262A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023005207A2 (cg-RX-API-DMAC10.html)
CA (1) CA3193347A1 (cg-RX-API-DMAC10.html)
ES (1) ES2994955T3 (cg-RX-API-DMAC10.html)
IL (1) IL301536A (cg-RX-API-DMAC10.html)
MX (1) MX2023003344A (cg-RX-API-DMAC10.html)
WO (1) WO2022066916A1 (cg-RX-API-DMAC10.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7844452B2 (ja) 2020-09-23 2026-04-13 トランスレイト バイオ, インコーポレイテッド Tesベースのカチオン性脂質
WO2022099003A1 (en) 2020-11-06 2022-05-12 Sanofi Lipid nanoparticles for delivering mrna vaccines
BR112023020027A2 (pt) * 2021-04-15 2023-11-14 Translate Bio Inc Lipídeos catiônicos baseados em tampão "good"
KR20240117084A (ko) 2021-11-29 2024-07-31 더 거버닝 카운실 오브 더 유니버시티 오브 토론토 멀티-모티프 덴드론 및 이의 초분자 구조체 그리고 이들의 용도
EP4493548A1 (en) * 2022-03-16 2025-01-22 Translate Bio, Inc. Asymmetric piperazine-based cationic lipids
CN121318878A (zh) 2022-04-13 2026-01-13 赛诺菲 基于“古德”缓冲液的阳离子脂质
US20240150306A1 (en) * 2022-09-27 2024-05-09 Reinvigoron Theratech, Inc. Compounds with cleavable disulfide moieties
TW202438514A (zh) 2022-12-20 2024-10-01 法商賽諾菲公司 鼻病毒mrna疫苗
CN116082275B (zh) * 2023-03-13 2023-07-14 北京悦康科创医药科技股份有限公司 一种脾脏中高表达的阳离子脂质化合物、包含其的组合物及用途
WO2025003760A1 (en) 2023-06-28 2025-01-02 Sanofi Sterol analogs in lipid nanoparticle formulations
US12599560B2 (en) 2023-11-02 2026-04-14 Longuide Biopharma Corporation Lipids and lipid nanoparticle formulations
WO2025091377A1 (en) * 2023-11-02 2025-05-08 Longuide Biopharma Corporation Lipids and lipid nanoparticle formulations
US12539279B2 (en) 2023-12-11 2026-02-03 The Governing Council Of The University Of Toronto Supramolecular ionizable lipid molecules with heteroatomic tuning for nucleic acid delivery
WO2025141521A1 (en) 2023-12-29 2025-07-03 Sanofi Lipids having dendritic moieties
WO2025160118A1 (en) * 2024-01-22 2025-07-31 The Trustees Of The University Of Pennsylvania Compositions and methods for hematopoietic stem cell (hsc) targeted delivery of therapeutic agents
WO2025255534A1 (en) * 2024-06-07 2025-12-11 Innovac Therapeutics Hk Limited Diol-based novel ionizable lipids and their uses thereof
WO2026008743A1 (en) 2024-07-02 2026-01-08 Sanofi Pasteur Inc. Water-soluble polyanionic polymer as adjuvant for carrier-formulated nucleic acid
WO2026053147A1 (en) 2024-09-05 2026-03-12 Sanofi Pasteur Inc. Helper lipids and lnp compositions comprising same
CN121627601B (zh) * 2026-01-30 2026-05-08 深圳市艾迪贝克生物医药有限公司 阳离子脂质化合物及其构建的脂质纳米颗粒、药物组合物和用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4401796A (en) 1981-04-30 1983-08-30 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
US7101995B2 (en) * 2001-08-27 2006-09-05 Mirus Bio Corporation Compositions and processes using siRNA, amphipathic compounds and polycations
KR20220038506A (ko) 2009-06-10 2022-03-28 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
WO2014028487A1 (en) 2012-08-13 2014-02-20 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
ES3032935T3 (en) * 2013-10-22 2025-07-29 Translate Bio Inc Lipid formulations for delivery of messenger rna
KR102559979B1 (ko) 2014-06-24 2023-07-25 샤이어 휴먼 지네틱 테라피즈 인크. 핵산의 전달용 입체화학적으로 풍부한 조성물
RS64331B1 (sr) * 2015-06-19 2023-08-31 Massachusetts Inst Technology Alkenil supstituisani 2,5-piperazindioni i njihova primena u sastavima za isporuku agensa u organizam ili ćeliju subjekta
WO2018087753A1 (en) * 2016-11-08 2018-05-17 Technology Innovation Momentum Fund (Israel) Limited Partnership Cationic lipids for nucleic acid delivery and preparation thereof
US20180153822A1 (en) 2016-11-10 2018-06-07 Translate Bio, Inc. Process of Preparing mRNA-Loaded Lipid Nanoparticles
WO2020023533A1 (en) * 2018-07-23 2020-01-30 Translate Bio, Inc. Dry power formulations for messenger rna
KR102860605B1 (ko) 2018-11-09 2025-09-15 트랜슬레이트 바이오 인코포레이티드 에스테르, 티오에스테르, 이황화물, 및 무수물 모이어티가 삽입된 2,5-디옥소피페라진
WO2021226463A1 (en) 2020-05-07 2021-11-11 Translate Bio, Inc. Composition and methods for treatment of primary ciliary dyskinesia
WO2021226468A1 (en) 2020-05-07 2021-11-11 Translate Bio, Inc. Improved compositions for cftr mrna therapy
US12576030B2 (en) * 2020-11-09 2026-03-17 Translate Bio, Inc. Compositions for delivery of codon-optimized mRNA

Also Published As

Publication number Publication date
JP7791182B2 (ja) 2025-12-23
BR112023005207A2 (pt) 2023-04-25
EP4216933A1 (en) 2023-08-02
CA3193347A1 (en) 2022-03-31
MX2023003344A (es) 2023-06-05
EP4216933C0 (en) 2024-09-18
US20230357166A1 (en) 2023-11-09
WO2022066916A1 (en) 2022-03-31
ES2994955T3 (en) 2025-02-04
JP2023542944A (ja) 2023-10-12
CN116457027A (zh) 2023-07-18
AU2021349262A9 (en) 2025-03-13
KR20230074526A (ko) 2023-05-30
EP4216933B1 (en) 2024-09-18
IL301536A (en) 2023-05-01

Similar Documents

Publication Publication Date Title
EP4216933B1 (en) Piperazine-based cationic lipids
AU2022259686A1 (en) "good"buffer-based cationic lipids
EP4126813A1 (en) Phenolic acid lipid based cationic lipids
US20260021055A1 (en) Asymmetric Piperazine-Based Cationic Lipids
JP7844452B2 (ja) Tesベースのカチオン性脂質
WO2025003759A9 (en) Dianhydrohexitol based ionizable lipids for nucleic acid delivery
AU2024306474A1 (en) Helper lipids for nucleic acid delivery
AU2023408649A1 (en) Bis-ester and amide cationic lipids
WO2025061967A1 (en) "good" buffer-based cationic lipids for nucleic acid delivery
WO2024256457A1 (en) Tricine and citric acid-based cationic lipids with aromatic head groups
EP4724456A1 (en) Sterol-based cationic lipids with aromatic head groups
US20240270707A1 (en) "Good" buffer-based cationic lipids
HK40099554B (en) Piperazine-based cationic lipids
HK40099554A (en) Piperazine-based cationic lipids

Legal Events

Date Code Title Description
SREP Specification republished